# PRAME

Source: https://onco.cc/targets/prame/  
OnCo record `prame` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRAME is a cancer-testis antigen: a protein normally confined to the testis that about 90% of cutaneous melanomas and substantial fractions of ovarian, lung, endometrial and uveal cancers switch on. Because it sits inside the cell, drugs reach it only as peptide fragments displayed on HLA, through T-cell receptor bispecifics such as brenetafusp and TCR-T cells such as IMA203.

## Summary

Preferentially Expressed Antigen in Melanoma is a cancer-testis antigen expressed in ~90% of cutaneous melanomas and in substantial fractions of ovarian, lung, endometrial, and uveal cancers. Intracellular, so reachable only via peptide-HLA recognition: brenetafusp (ImmTAC), IMA203 (Immatics TCR-T, phase 3 in melanoma), and other TCR programmes. PRAME immunohistochemistry is also a diagnostic aid for distinguishing melanoma from naevi.

## Fields

- Kind: Target
- Last checked: 2026-09-07
- Tags: tcr-target
- Symbol: PRAME
- Class: other
- Biology: Represses retinoic acid receptor signalling; drives proliferation and blocks differentiation; presented on HLA class I as peptides such as PRAME 425-433 on A*02:01.
- Where found: Cutaneous melanoma (~90%); Uveal melanoma (subset, associated with metastasis); Ovarian, endometrial, NSCLC, breast (subsets); Synovial sarcoma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/PRAME
- Wikipedia: https://en.wikipedia.org/wiki/PRAME

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- drugs: [Brenetafusp](https://onco.cc/drugs/brenetafusp/), [IMA203](https://onco.cc/drugs/ima203/)
- companies: [Immatics](https://onco.cc/companies/immatics/), [Immunocore](https://onco.cc/companies/immunocore/)
- terms: [HLA-A*02:01 restriction](https://onco.cc/terms/hla-a02-restriction/), [Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)](https://onco.cc/terms/uveal-melanoma-prognostic-markers/)
- trials: [IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors](https://onco.cc/trials/nct05958121/), [PRISM-MEL-301](https://onco.cc/trials/prism-mel-301/)
- ideas: [TCR therapeutics for non-HLA-A*02 patients](https://onco.cc/ideas/idea-prame-tcr-beyond-a02/)
- pathways: [Antigen presentation & immune editing](https://onco.cc/pathways/antigen-presentation-immunoediting/)
- targets: [HLA-A](https://onco.cc/targets/hla-a/)

---
JSON: https://onco.cc/api/v1/entities/prame.json